key: cord-0727759-odqfmc3p
authors: Azzi, Lorenzo; Toia, Marco; Stevanello, Nicole; Maggi, Fabrizio; Forlani, Greta
title: An episode of oral mucositis after the first administration of the ChAdOx1 COVID‐19 vaccine
date: 2021-04-19
journal: Oral Dis
DOI: 10.1111/odi.13874
sha: 6b520896b099f118276301ae42d79698a21f7a1b
doc_id: 727759
cord_uid: odqfmc3p

nan

To the Editor:

The case here reported presents some clinical signs and symptoms which could be associated with the first dose administration of the ChAdOx1 COVID-19 vaccine, thus suggesting the onset of side effects not described so far.

A 31-year-old woman was referred to our clinic complaining of moderate, burning pain in her mouth. Three days prior to her visit, she had received the first dose of the ChAdOx1 COVID-19 vaccine, batch ABV2856, and twenty-four hours after vaccination, she had reported symptoms such as fever, headache, myalgia, arthralgia and fatigue, commonly associated with the vaccine administration.

The clinical examination of her mouth showed the presence of diffuse, erythematous and swollen red lesions on her buccal mucosa, tongue, gums and palate ( Figure 1 ).

The patient's medical history revealed a single episode of deep vein thrombosis in her right arm in June 2020, and the presence of heterozygous Factor V Leiden mutation. More importantly, she had never been diagnosed with SARS-CoV-2 infection, either by NAAT or by serological testing. She only took an oral contraceptive.

The lesions were successfully treated with topical corticosteroids (i.e. Betamethasone effervescent tablets 1 mg three times per day, with progressive dose reduction) and topical miconazole oral gel 2%. They healed after three days.

ChAdOx1 is one of the approved COVID-19 vaccines and is currently being distributed in the general population in many countries . Consistently, our patient was diagnosed with a heterozygous Factor V Leiden mutation, a condition that is associated with a 5-fold to 10-fold increase in thromboembolic events when compared with the non-affected population (Zermatten et al., 2020) . This condition may have favoured the onset of oral mucositis. However, oral mucositis can be regarded as a minor side effect, and the benefit of the immune protection acquired after vaccination outweighs the risks linked to COVID-19 thromboembolism, which is more common in this group of patients.

Further reports are needed to assess whether oral mucositis may be considered a minor side effect of ChAdOx1 vaccine, while treatment with topical corticosteroids has proved to be effective in reducing the patient's discomfort and speeding up the healing

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind

Oral mucositis in a SARS-CoV-2-infected patient: Secondary or truly associated condition

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials

Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptoves: A case report